The global angiotensin converting enzymes (ACE) inhibitors market size was around USD 11,693 million in 2020 and is projected to register a CAGR of 3.1%, during the forecast period, 2021-2028. The growth of the market is attributed to rising prevalence of cardiovascular diseases across the globe.
ACE inhibitor is administered to control high blood pressure and are used for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraine.
These enzymes relax the blood vessels as well as decrease blood flow, which leads to lower blood pressure, and decreases the oxygen demand from the heart. Benazepril, captopril, enalapril, cilazapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril are some of the ACE inhibitors used for treating hypertension.
Market Drivers, Restraints, Trends, and Opportunities
- Growing adoption of ACE Inhibitors in the management of chronic disorders is projected to drive the market growth.
- Increasing prevalence of hypertension and other cardiovascular disorders is driving the demand for ACE inhibitors.
- Rising demand for inexpensive drugs to manage medical complications related to heart is expected to have a positive impact on the growth of the global ACE inhibitors market.
- Side effects associated with the treatment, such as the increased risk of lung cancer can hamper the market growth.
Scope of the Report
The report on the global angiotensin converting enzyme (ACE) inhibitors market includes an assessment of the market, trends, segments and regional markets. Overview and dynamics have also been included in the report.
Global Angiotensin Converting Enzyme (ACE) Inhibitors Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Types (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, and Phosphonate-containing Agents), and Applications (Hypertension, Cardiovascular Diseases, Kidney Diseases, and Others)
North America, Latin America, Europe, Asia Pacific and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Inc., Pfizer, Inc., AbbVie Inc., AstraZeneca, Bausch Health Companies, Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Silvergate Pharmaceuticals, Inc.
Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Segment Insights
Sulfhydryl-containing agents segment to account a significant market share
Based on types, the ACE inhibitors market is segregated into sulfhydryl-containing agents, dicarboxylate-containing agents and phosphonate-containing Agents. The sulfhydryl-containing agents segment is anticipated to account for a considerable market share during the forecast period. On the other hand, the dicarboxylate-containing agents is expected to grow at a steady rate during the forecast period.
Diabetes segment is projected to expand at a high CAGR
Based on applications, the market is segregated into hypertension, cardiovascular diseases, kidney diseases, and others. The diabetes segment is expected to expand at a high CAGR during the forecast period. Rising cases of type 2 diabetes is driving the segment growth.
The cardiovascular diseases segment to account for a large market share during the forecast period. ACE inhibitors play a key role in the management of heart failure. Increasing prevalence of cardiovascular diseases is anticipated to spurn the segment growth. The hypertension segment is expected to hold a significant market share in the ACE inhibitors market. Primary hypertension is the prevalent form of hypertension, affecting about 95% of hypertensive patients. Rising incidence of hypertension is speculated to increase the demand for ACE inhibitors, driving the growth of the market segment.
North America is expected to dominate the market
Based on regions, the ACE inhibitors market is classified as, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America is expected to dominate the market owing to rising prevalence of cardiovascular diseases and incidence of hypertension in the US and Canada.
The market in Asia Pacific is expected to exhibit a high CAGR during the forecast period. Rising population and swift development in the healthcare sector are driving the regional market growth. Additionally, increasing cases of cardiac diseases in countries such as India and China are expected to drive the growth of the market in the region. The market in Middle East and Africa is expected to expand at a moderate growth in the ACE inhibitors market due to limited access to advanced healthcare infrastructure.
Segments Covered in the Report
The global angiotensin converting enzymes (ACE) inhibitors market has been segmented on the basis of
- Sulfhydryl-containing Agents
- Dicarboxylate-containing Agents
- Phosphonate-containing Agents
- Cardiovascular Diseases
- Kidney Diseases
- North America
- Latin America
- Asia Pacific
- Middle East
- Bristol-Myers Squibb Company
- Par Pharmaceutical Companies, Inc.
- UCB, Inc.
- Pfizer, Inc.
- AbbVie, Inc.
- Bausch Health Companies, Inc.
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Silvergate Pharmaceuticals, Inc.
Major players of the market are Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Inc., Pfizer, Inc., AbbVie Inc., AstraZeneca, Bausch Health Companies, Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Silvergate Pharmaceuticals, Inc.
Various major pharmaceutical companies are developing innovative products that are contributing to the growth of the market. For instance, in January 2017, Silvergate Pharmaceuticals, Inc. launched Epaned to tackle hypertension and heart failure. It was the first ready to use ACE inhibitor in oral solution form.